Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo.
Curcumin, the main compound of spice turmeric, is one of the natural products that has been shown to possess effective anti-cancer properties. However, the absorption efficacy of curcumin is too low to make dramatic results in therapy. Therefore, we based the main aim of this study on improving the bioavailability of curcumin taking advantage of dendrosome nanoparticles; and subsequently evaluating in vitro and in vivo anti-tumor properties of dendrosomal curcumin. In vitro studies were carried out utilizing A431 and WEHI-164 cell lines and mouse embryonic normal fibroblasts. Our data revealed that dendrosomal curcumin not only exhibits a much higher bioavailability than void curcumin (P<0.05) but also inhibits the proliferation of cancer cells (P<0.01) in a time- and dose-dependent manner that could be ascribed to the induction of apoptosis. However, dendrosome did not indicate any toxic effect on different types of cell lines. For in vivo studies, BALB/c tumor-bearing mice were treated with dendrosomal curcumin, void curcumin, dendrosome and PBS. The results indicated that dendrosomal curcumin reduces significantly the tumor size in comparison with void curcumin and control samples (P<0.05). Furthermore, in animals treated with dendrosomal curcumin a longer survival was observed (P<0.01). We also found that the mice treated with dendrosomal curcumin, showed a significant increase in splenocyte proliferation and IFN-γ production as well as a significant decrease in IL-4 production. This can be a proof of anti-tumor immunity caused by dendrosomal curcumin. The findings demonstrate that dendrosomal curcumin offers a great potential to be a promising anti-cancer therapeutic agent.